NCT04111666已完成1 期
A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Bioavailability of IV and SC AL101
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Alector Inc.
- 入组人数
- 88
- 试验地点
- 2
- 主要终点
- Evaluation of safety and tolerability of AL101 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)
研究概览
简要总结
A first in human phase 1 study in healthy volunteers to assess AL101 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics
详细描述
This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK, PD and Bioavailability of intravenously and sub-cutaneously administered AL101 in Healthy Volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •BMI 18.0-35.0 kg/m2
- •45-120 kg, inclusive
- •At screening, females must be non-pregnant and non-lactating, or of nonchildbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1-year postmenopausal (amenorrhoea duration of 12 consecutive months); nonpregnancy will be confirmed for all females by a pregnancy test conducted at screening, (each) admission, and at follow-up.
- •Female participants of child-bearing potential must agree to use adequate contraception from screening until 90 days after the follow-up visit.
- •In good physical health on the basis of no clinically significant findings from medical history, physical examination (PE), laboratory tests, 12 lead ECG, and vital signs, as judged by the Investigator.
- •Willingness and able to comply with the study protocol, in the investigator's judgement.
排除标准
- •Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
- •Positive drug or alcohol at screening and prior to first dose
- •History of alcohol abuse or substance abuse
研究组 & 干预措施
AL101 SC
Experimental
- Single fixed dose levels of AL101 administered SC
- Multiple fixed dose of AL101 administered SC
干预措施: AL101 (Biological)
Saline Solution
Placebo Comparator
Saline solution will be administered with the following:
- Single IV infusion for four single ascending doses (SAD IV cohorts) in a ratio of 8 active and 3 placebo subjects
- Multiple IV infusions for the MD IV cohort in a ratio of 8 active and 2 placebo subjects
干预措施: Placebo (Other)
AL101 IV
Experimental
- Up to four single ascending doses (SAD IV cohorts)
- Multiple doses of AL101 administered IV (MD IV cohort)
干预措施: AL101 (Biological)
结局指标
主要结局
Evaluation of safety and tolerability of AL101 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)
时间窗: either 57, 113, or 141 days, depending on the cohort
Incidence of adverse events and dose limiting Adverse Events during the DLAE observation period and/or study treatment periods.
次要结局
- Pharmacokinetics (PK) of AL101(either 57, 113, or 141 days, depending on the cohort)
- Area under the curve concentration (AUC) for AL101(either 57, 113, or 141 days, depending on the cohort)
- Maximum plasma concentration (Cmax) for AL101(either 57, 113, or 141 days, depending on the cohort)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
A Study to Evaluate the Safety of MAX-40070 in Healthy SubjectsAlopecia AreataNCT05196711Maxinovel Pty., Ltd.78
已完成
1 期
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT06422520BeOne Medicines63
终止
1 期
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT05821777Centessa Pharmaceuticals (UK) Limited25
已完成
1 期
HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-humanRhinoconjunctivitis, AllergicRhinitis, AllergicNCT03758456HAL Allergy45
已完成
1 期
Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical CarcinomaAdrenal CancerACCAdrenocortical CarcinomaNCT01898715Millendo Therapeutics, Inc.63